Latest Healthcare News

Epsilon Healthcare and its subsidiaries have officially exited voluntary administration and Deeds of Company Arrangement, marking a pivotal recovery milestone supported by significant personal commitments from the new board. The company now shifts focus to strategic growth and rebuilding trust.

Oceania Holdings Limited showcased robust operational progress and a strategic pivot towards portfolio modernization at its 2025 Annual Meeting, while announcing a new cost savings program and withholding its final dividend for FY25.

Oceania Healthcare’s CEO delivered a confident first AGM address highlighting robust sales growth, operational efficiencies, and a refreshed strategic vision focused on care quality and sustainability.

Oceania Healthcare has modernized its property portfolio and updated its dividend policy to align with a new strategic direction under CEO Suzanne Dvorak, aiming to meet New Zealand's growing aged care demand.

Atomo Diagnostics has successfully closed a Share Purchase Plan and secured shareholder approval for a Tranche 2 Placement, raising a combined $1.53 million to support its ongoing operations.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.

Orthocell has marked a pivotal milestone with the first US surgical use of its Remplir™ nerve repair device following FDA clearance, setting the stage for commercial expansion in a $1.6 billion market.

Adherium Limited has announced a partially underwritten entitlement offer aiming to raise approximately A$4.5 million through the issuance of new shares and options at a significant discount. The capital raise is designed to accelerate patient onboarding and product development for its respiratory monitoring technology.

Adherium Limited has successfully closed the institutional portion of its entitlement offer, increasing the raise to $4.492 million due to robust demand. The company now invites retail shareholders to participate as it advances its digital respiratory health solutions.

Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.

Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.

Singular Health Group has completed a $7.85 million capital raising through a new share issue, alongside additional funds from option exercises, strengthening its financial position for growth in medical imaging technology.